Whelan Financial Sells 36 Shares of Eli Lilly and Company $LLY

Whelan Financial lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 429 shares of the company’s stock after selling 36 shares during the period. Whelan Financial’s holdings in Eli Lilly and Company were worth $335,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. WestEnd Advisors LLC grew its holdings in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at $27,000. Citizens National Bank Trust Department grew its holdings in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at $40,000. Finally, TD Capital Management LLC grew its holdings in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 2.5%

Shares of NYSE LLY opened at $840.46 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The stock has a market cap of $795.47 billion, a P/E ratio of 54.93, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The firm has a 50-day moving average of $734.60 and a 200 day moving average of $766.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the company posted $3.92 EPS. Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. HSBC raised shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and raised their target price for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. JPMorgan Chase & Co. dropped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. Finally, Morgan Stanley dropped their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $933.39.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 over the last 90 days. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.